Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Cell Oncol ; 31(1): 11-7, 2009.
Article in English | MEDLINE | ID: mdl-19096146

ABSTRACT

BACKGROUND: A variety of molecular markers have been evaluated for the development of a non-invasive approach to the diagnosis of colorectal cancer. We aimed to validate the diagnostic accuracy, using the same threshold as in the previous pilot study, of fluorescent long DNA test as a relatively simple and inexpensive tool for colorectal cancer detection. METHODS: A case-control study was conducted on 100 healthy subjects and 100 patients at first diagnosis of colorectal cancer. Human long-fragment DNA in stool was quantified by fluorescence primers and a standard curve and expressed in DNA nanograms. RESULTS: We validated the 25-ng value, which emerged as the most accurate cut-off in the pilot study, obtaining 79% (95% CI, 71-87%) sensitivity and 89% (95% CI, 83-95%) specificity. Specificity was very high for all cut-off values (15-40 ng) analyzed, ranging from 78 to 96%. Sensitivity was only slightly lower, reaching 84% at the lowest cut-off and maintaining a good level at the higher values. Diagnostic potential was independent of gender, age and tumor site. CONCLUSION: Fecal DNA analysis is a non-invasive and fairly simple test showing high diagnostic potential. These characteristics, together with the small amount of stool required, make it potentially suitable to be used alongside or as an alternative to current non-invasive screening approaches. Our next step will be to validate these results in a large-scale cohort study of a screening population, which is needed prior to implementation into clinical practice.


Subject(s)
Biomarkers, Tumor/genetics , Colorectal Neoplasms/diagnosis , Colorectal Neoplasms/genetics , DNA/genetics , Early Detection of Cancer , Feces/chemistry , Adenomatous Polyposis Coli Protein/genetics , Aged , Aged, 80 and over , Case-Control Studies , DNA Primers/genetics , Female , Fluorescent Dyes/chemistry , Humans , Male , Middle Aged , Polymerase Chain Reaction , Tumor Suppressor Protein p53/genetics
2.
J Clin Gastroenterol ; 42 Suppl 3 Pt 2: S218-23, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18685503

ABSTRACT

OBJECTIVES: Efficacy of symbiotics in patients with irritable bowel syndrome (IBS) remains unknown. METHODS: Patients were randomized to a prebiotic (n=135), or a symbiotic formulation containing Lactobacillus paracasei B21060 (Flortec, n=132). Primary efficacy was the responder rate for pain and global relief of symptoms in the overall population and in patients with predominant diarrhea (n=47). Post hoc time-trend analyses for changes within each treatment were carried out. RESULTS: Patients with absent/mild pain amounted to 54.7% in the symbiotic group and to 57.4% in the prebiotic group at treatment week 4, and to 53.9% and 53.4% at the end of treatment. Patients with amelioration of well-being were, respectively, 60.7% versus 61.7% at treatment week 4, and 63.3% versus 60.9% at the end of treatment. Within each treatment group, patients with absent/mild pain increased in the Flortec and the prebiotic group, but time trend analyses were significant only for Flortec (P=0.019). In IBS-predominant diarrhea, Flortec significantly reduced bowel movements, pain, and IBS scores. CONCLUSIONS: To improve pain and well-being, Flortec is encouraging in patients with diarrhea predominant IBS. To establish its efficacy for the majority of IBS patients, Flortec has to be compared with an inert placebo in future work.


Subject(s)
Glutamine , Irritable Bowel Syndrome/therapy , Lactobacillus , Oligosaccharides , Probiotics , Adult , Double-Blind Method , Drug Synergism , Female , Glutamine/administration & dosage , Glutamine/therapeutic use , Humans , Irritable Bowel Syndrome/physiopathology , Male , Middle Aged , Oligosaccharides/administration & dosage , Oligosaccharides/therapeutic use , Probiotics/administration & dosage , Probiotics/therapeutic use , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...